A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (VITAL)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00532155 |
Recruitment Status :
Completed
First Posted : September 20, 2007
Results First Posted : January 1, 2013
Last Update Posted : June 7, 2016
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
The primary objective of the study was to demonstrate overall survival improvement for aflibercept + docetaxel compared to docetaxel + placebo as second line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC).
The secondary objectives were to compare other efficacy parameters, to assess the overall safety of the two treatment arms, to assess the pharmacokinetics of intravenous (IV) aflibercept in this participant population and to determine immunogenicity of IV aflibercept in all participants.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Carcinoma Non Small Cell Lung | Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) Drug: Placebo Drug: Docetaxel (Taxotere®) Drug: Dexamethasone (pre- and post-medication for docetaxel) | Phase 3 |
The study included:
- A screening visit of up to 21 days prior to randomization
- Randomization at baseline (Treatment was initiated with 3 days of randomization)
- A treatment period with 3-week treatment cycles until the participant met the following discontinuation criteria: had progressive disease, had unacceptable toxicity, or refused further study treatment
- A post study treatment follow-up period (a visit was scheduled every 8 weeks until death or end of study)
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 913 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Multinational, Randomized, Double-Blind Study Comparing Aflibercept Versus Placebo in Patients Treated With Second-Line Docetaxel After Failure of One Platinum Based Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer |
Study Start Date : | September 2007 |
Actual Primary Completion Date : | January 2011 |
Actual Study Completion Date : | October 2011 |

Arm | Intervention/treatment |
---|---|
Experimental: Placebo/Docetaxel
Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Placebo immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal.
|
Drug: Placebo
Matching placebo to Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks. Drug: Docetaxel (Taxotere®) 75 mg/m² docetaxel in 250 mL dextrose 5% or NaCl 0.9% administered intravenously (IV) over 1 hour, on Day 1 every 3 weeks. Drug: Dexamethasone (pre- and post-medication for docetaxel) As a pre- and post-medication for docetaxel, 8 mg dexamethasone was administered orally, the evening before Day 1, on Day 1 (early morning, 1 hour before docetaxel treatment, and evening) and on Day 2 (morning and evening). |
Placebo Comparator: Aflibercept/Docetaxel
Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Aflibercept immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal.
|
Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
6 mg/kg Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks. Drug: Docetaxel (Taxotere®) 75 mg/m² docetaxel in 250 mL dextrose 5% or NaCl 0.9% administered intravenously (IV) over 1 hour, on Day 1 every 3 weeks. Drug: Dexamethasone (pre- and post-medication for docetaxel) As a pre- and post-medication for docetaxel, 8 mg dexamethasone was administered orally, the evening before Day 1, on Day 1 (early morning, 1 hour before docetaxel treatment, and evening) and on Day 2 (morning and evening). |
- Overall Survival (OS) [ Time Frame: Baseline to the date when 687 deaths occurred (26 January 2011) ]
OS was time interval from the date of randomization to the date of death due to any cause. If death was not observed during the study, overall survival time was censored at the last date the participant was known to be alive, or the study cutoff date, whichever was earlier. The cut-off date for the OS was date when 687 deaths were observed.
OS was estimated from Kaplan-Meier Curves.
- Progression Free Survival (PFS) [ Time Frame: Baseline to data cut-off (26 January 2011) ]
PFS was defined as the time interval between the date of randomization and the time of occurrence of the first radiological tumor progression detected by a computer tomography (CT) scan and /or by Magnetic Resonance Imaging (MRI); or death due to any cause; whichever was earlier. Participants without disease progression were censored at the earliest date between their last valid tumour assessment and the data cutoff date.
PFS was estimated from Kaplan-Meier Curves.
- Overall Response (OR) Rate as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria [ Time Frame: Baseline to data cut-off (26 January 2011) ]
Participants with OR were those who had a confirmed complete response [CR] or a confirmed partial response [PR], based on RECIST criteria, in which
- CR refected the disappearance of all tumor lesions (with no new tumors)
- PR reflected a pre-defined decrease in tumor burden - a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD
- OR was CR + PR The response rate was the percent of participants with a response.
To determine a response, tumors were assessed by the investigators using Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and an observed response was confirmed by repeated imaging after 4 - 6 weeks.
- Health Related Quality of Life (HRQL) Assessed by the Lung Cancer Symptom Scale (LCSS) [ Time Frame: Baseline (prior to first dose), at cycles 2 and 4 and at the end of study therapy. ]HRQL assessments were performed by participants using a self-administered LCSS questionnaire. LCSS is a 9-item questionnaire, six measuring major symptoms for lung malignancies (appetite, fatigue, cough, dyspnea, hemoptysis and pain), and 3 summation items related to total symptomatic distress, activity status and overall quality of life. Participant responses were measured using visual analogue scales (VAS) with 100-mm lines. The LCSS total score was defined as the mean of the 9 items of the scale, each scored between 0 (for best outcome) to 100 (for worst outcome).
- Health Related Quality of Life (HRQL) Assessed by the Average Symptom Burden Index (ASBI) [ Time Frame: Baseline (prior to first dose), at cycles 2 and 4 and at the end of study therapy. ]HRQL assessments were performed by participants using a self-administered LCSS questionnaire. LCSS is a 9-item questionnaire, six measuring major symptoms for lung malignancies, and 3 summation items related to total symptomatic distress, activity status and overall quality of life. Participant responses were measured using visual analogue scales (VAS) with 100-mm lines. ABSI was the mean score for the six major lung cancer symptoms (appetite, fatigue, cough, dyspnea, hemoptysis and pain), each scored between 0 (for best outcome) to 100 (for worst outcome).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histological/cytological proven locally advanced or metastatic non-small cell lung cancer
- Disease progression during or after one, and only one, prior anticancer therapy which is platinum-based for advanced or metastatic disease
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
- Adequate renal, liver and bone marrow functions
Exclusion Criteria:
- Squamous histology/cytology
- Less than 28 days elapsed from prior treatment with radiotherapy, surgery, or chemotherapy to the time of randomization
- Prior isotope therapy, whole pelvic radiotherapy, or radiotherapy to > 25% of bone marrow
- Prior docetaxel treatment
- Uncontrolled hypertension
The above information was not intended to contain all considerations relevant to participation in a clinical trial.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00532155
United States, New Jersey | |
Sanofi-Aventis Administrative Office | |
Bridgewater, New Jersey, United States, 08807 | |
Argentina | |
Sanofi-Aventis Administrative Office | |
Buenos Aires, Argentina | |
Australia, New South Wales | |
sanofi-aventis Australia & New Zealand administrative office | |
Macquarie Park, New South Wales, Australia | |
Austria | |
Sanofi-Aventis Administrative Office | |
Wien, Austria | |
Brazil | |
Sanofi-Aventis Administrative Office | |
Sao Paulo, Brazil | |
Bulgaria | |
Sanofi-Aventis Administrative Office | |
Sofia, Bulgaria | |
Canada | |
Sanofi-Aventis Administrative Office | |
Laval, Canada | |
Chile | |
Sanofi-Aventis Administrative Office | |
Santiago, Chile | |
China | |
Sanofi-Aventis Administrative Office | |
Shangai, China | |
Czech Republic | |
Sanofi-Aventis Administrative Office | |
Praha, Czech Republic | |
Estonia | |
Sanofi-Aventis Administrative Office | |
Tallinn, Estonia | |
Finland | |
Sanofi-Aventis Administrative Office | |
Helsinki, Finland | |
France | |
Sanofi-Aventis Administrative Office | |
Paris, France | |
Germany | |
Sanofi-Aventis Administrative Office | |
Berlin, Germany | |
Greece | |
Sanofi-Aventis Administrative Office | |
Athens, Greece | |
Hong Kong | |
Sanofi-Aventis Administrative Office | |
Causeway Bay, Hong Kong | |
Hungary | |
Sanofi-Aventis Administrative Office | |
Budapest, Hungary | |
India | |
Sanofi-Aventis Administrative Office | |
Mumbai, India | |
Italy | |
Sanofi-Aventis Administrative Office | |
Milano, Italy | |
Korea, Republic of | |
Sanofi-Aventis Administrative Office | |
Seoul, Korea, Republic of | |
Malaysia | |
Sanofi-Aventis Administrative Office | |
Kuala Lumpur, Malaysia | |
Netherlands | |
Sanofi-Aventis Administrative Office | |
Gouda, Netherlands | |
Poland | |
Sanofi-Aventis Administrative Office | |
Warszawa, Poland | |
Portugal | |
Sanofi-Aventis Administrative Office | |
Porto Salvo, Portugal | |
Romania | |
Sanofi-Aventis Administrative Office | |
Bucuresti, Romania | |
Russian Federation | |
Sanofi-Aventis Administrative Office | |
Moscow, Russian Federation | |
Singapore | |
Sanofi-Aventis Administrative Office | |
Singapore, Singapore | |
Spain | |
Sanofi-Aventis Administrative Office | |
Barcelona, Spain | |
Sweden | |
Sanofi-Aventis Administrative Office | |
Bromma, Sweden | |
Taiwan | |
Sanofi-Aventis Administrative Office | |
Taipei, Taiwan | |
Turkey | |
Sanofi-Aventis Administraive Office | |
Istanbul, Turkey | |
United Kingdom | |
Sanofi-Aventis Admnistrative Office | |
Guildford Surrey, United Kingdom |
Study Director: | Clinical Sciences & Operations | Sanofi |
Responsible Party: | Sanofi |
ClinicalTrials.gov Identifier: | NCT00532155 |
Other Study ID Numbers: |
EFC10261 EudraCT 2007-000819-29 |
First Posted: | September 20, 2007 Key Record Dates |
Results First Posted: | January 1, 2013 |
Last Update Posted: | June 7, 2016 |
Last Verified: | May 2016 |
lung cancer angiogenesis inhibitor chemotherapy |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Dexamethasone Docetaxel Aflibercept Anti-Inflammatory Agents Antiemetics |
Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Angiogenesis Inhibitors Angiogenesis Modulating Agents |